Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: Updated 5-year survival rates and genomic analysis - Planchard, D; Besse, B; Groen, H JM (J Thorac Oncol, 2022)